ANRO vs DRUG
ANRO: Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted therapies. DRUG: Bright Minds Biosciences is a clinical-stage biotechnology company developing next-generation serotonin-targeting therapies for neuropsychiatric, epilepsy, and pain conditions.
Side-by-side fundamentals
| Metric | ANRO | DRUG | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $27.23 | $75.46 | |
| Market cap as of 2026-07-23 | $1.0B | $762M | |
| PEG as of 2026-07-23 | -1.82 | -0.06 | ANRO lower |
| Net margin as of 2026-07-23 | -4374.8% | n/a | |
| Operating margin as of 2026-07-23 | -5740.9% | n/a | |
| ROE as of 2026-07-23 | -47.2% | -20.6% | DRUG higher |
| ROA as of 2026-07-23 | -38.8% | -20.3% | DRUG higher |
| Debt / equity as of 2026-07-23 | 0.08 | 0.00 | DRUG lower |
| Beta as of 2026-07-23 | 2.32 | 2.30 | |
| 1-year return as of 2026-07-22 close | +891.6% | -74.8% | ANRO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.